Posts

AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical - Recent News

on

AstraZeneca seals near $1.8B renal disease pact with CSPC

on

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

on

Insilico lands heavily backloaded $2.5B AI drug discovery deal with SK Biopharm

on

Lilly allies with BioArctic

on

Merck adds to biopharma’s AI agenda with up to $510M+ Protillion pact

on

Novartis tightens bond with Orionis in up to $1.4B molecular glue deal - Biospace, European Biotechnology, LinkedIn, etc.

on

Travere pays Everest $112.5M upfront to grow rare kidney disease pipeline

on

Pfizer signs up to $10.5B deal with Innovent for 12 early‑stage cancer drugs from China's biotech hub

on

Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling

on

Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS from Corium for $650 Million

on

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

on

Zymeworks Pivots to Royalty-Driven Model After Strong Ziihera Data in Gastric Cancer

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Roche Inks $80M Upfront Deal for Hansoh's Cancer ADC HS-20110

on

Behind-the-Scenes Details of 89bio's $2.4B Deal with Roche

on

Halozyme to Acquire Elektrofi for $750 Million, Expanding Drug Delivery Capabilities

on

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

on

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

on